Latest News

The banking giant in Latin America is growing quickly.

This company recently reported triple-digit revenue growth.

Recent news from the Trump Administration sent GE Vernova soaring last week.

Too many people are making growth investing more difficult -- and dangerous -- than it needs to be.

The Fidelity Wise Origin Bitcoin Fund tracks bitcoin directly, while the Bitwise Crypto Industry Innovators ETF invests in companies tied to the crypto economy. This ETF comparison shows why those differences matter when volatility picks up.

Broadcom is poised to be one of the biggest beneficiaries of increasing AI infrastructure spending.

Japan has officially reached the end game for central bank policy.

INTC, MRNA, TMC, MSFT, LCID were among the stocks seen trending on Wednesday, Jan. 21, 2026.

Join us as we dissect 3M's potential for growth and innovation. Can the company turn its fortunes around, or is it destined for mediocrity? Tune in to find out!

The vaccine maker is expanding beyond its COVID-focused offerings.

This stock has gained 370% over the past three years.

What’s particularly impressive about the company is not only its 8.7% distribution yield, but that it has raised its payout for 33 straight quarters, a span of more than eight years.

How much longer can stock investors ignore the elephant in the room?

There's reason to be optimistic about this exciting technology.

Stocks finished the day higher, reclaiming some of their losses on January 20, with the S&P 500 hitting the 78.6% retracement level of its Friday closing price.

One stock is clearly better on a risk/reward basis in 2026.

When the leveraged mispricing of risk collapses we may see something historic.

Gold price tumbles to around $4,790 in Thursday’s early Asian session.

Tariffs and global relations could be weighing on Trump's approval rating more than stock market returns according to a new poll.

The bullish case for the stock remains strong.

Over the last few days, we have seen a small selection of the best scenarios currently on the table.

The top voted question for Tesla leadership pertains to whether Tesla shareholders will be prioritized in the event of a SpaceX IPO.

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.